SWAN is pleased to announce an investment in Vasowatch, a maternal health technology company developing predictive technology to help clinicians identify postpartum hemorrhage risk before delivery.

Postpartum hemorrhage remains a leading cause of maternal death, yet many of these deaths are preventable with earlier detection and preparedness. Vasowatch’s innovative, non-invasive technology is designed to identify previously unknown hemorrhage risk hours before delivery—giving care teams critical time to prepare and intervene.

By enabling earlier, more proactive care, Vasowatch has the potential to help prevent postpartum hemorrhage and improve outcomes for mothers and families.